IRVINE, Calif., April 20 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. , a leading manufacturer of life-saving automated public-access defibrillators (AED) and provider of comprehensive AED/CPR training and AED program management services, announced that the Chiba Prefecture branch of the Japanese Medical Association (JMA) has purchased 300 private-labeled AEDs from Nihon Kohden Corporation (Tokyo: JP: 6849), Cardiac Science's OEM and distribution partner in Japan. The Chiba prefecture, which includes more than 3,000 institutions and 4,600 individual members, is expanding AED deployment and lifesaving training throughout its member institutions, including hospital and medical clinics in its region.
According to Kazuo Kawagoe, M.D., Director of Emergency Medicine of the Chiba Prefecture Branch of the JMA, Nihon Kohden-brand AEDs were chosen over competitive devices due to their ease of use and their unique reliability features unavailable on other units.
"The new laws allowing broader use of AEDs by ordinary Japanese citizens create both an opportunity and a responsibility in the healthcare field," said Dr. Kawagoe. "The Japanese Medical Association has identified AEDs as an important tool in our effort to improve medical care in our local communities. In addition, our members will be taking an active role to promote the deployment of AEDs in the public and train Japanese citizens how to effectively use AEDs to save cardiac arrest victims."
Cardiac Science Chairman and CEO Raymond W. Cohen said, "Japan is our most active market outside of the United States, and Nihon Kohden, Japan's largest medical patient monitoring and defibrillation manufacturer, is our most successful distribution partner. However, this is a nescient market which, until now, has been limited to airlines and medical facilities. During 2004 and beyond, we anticipate growing deployments of AEDs in additional segments such as first responders, corporations and public places. In the two years since Nihon Kohden starting selling Cardiac Science AEDs, more than 5,000 units have been sold in Japan and we are on track for continued growth in 2004."
About the Japanese AED market
In September 2003, the Japanese Ministry of Health, Labor and Welfare, for the first time, approved the use of automated external defibrillators (AEDs) by non-medical persons. The new law represented a significant shift in the Japanese ministry's view toward the use of AEDs, which formerly could only be legally used by physicians, paramedics and trained flight attendants in airplanes.
According to market analysis published by Frost & Sullivan, it is estimated that the worldwide market for AEDs will expand to more than 300,000 units a year by 2006, accounting for more than $650 million in annual revenue. The potential Japanese AED market is estimated to be as much as 20 percent the size of the combined U.S. and European markets. Potential AED users in Japan include approximately 89,000 medical and dental clinics, 53,000 police, fire and emergency vehicles, thousands commercial buildings and government facilities as well as 41,000 schools and 2,000 golf courses.
About Nihon Kohden Corporation
Nihon Kohden, based in Tokyo, Japan, develops, manufactures and distributes a variety of diagnostic medical devices including patient monitoring systems, electrocardiograms (EKGs), electroencephalograms (EEGs), cardiac monitors and external defibrillators and has annual revenue in excess of $500 million.
About Cardiac Science
Cardiac Science develops, manufactures and markets Powerheart(R)-brand public-access defibrillators (AEDs) and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The Company also makes the Powerheart(R) CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies. For more information, please visit http://www.cardiacscience.com/, email Cardiac Science at email@example.com or call toll free at 1-866-289-5649.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 2002 and other documents filed by the company with the Securities and Exchange Commission.
For further information please contact: investors, Matt Clawson, firstname.lastname@example.org, or media, Len Hall, email@example.com, both of Allen & Caron, Inc, +1-949-474-4300, for Cardiac Science, Inc.; or Michael Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, firstname.lastname@example.org.
Cardiac Science, Inc.